VI 16832 |
| Catalog No.GC32833 |
VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1430218-51-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
VI 16832 is a broad spectrum Type I kinase inhibitor[1]. Phosphoproteomics analysis of VI 16832-enriched fractions from MV4-11, HCT116, or 435S cells results in more than 8500 phosphopeptide identifications. These translate into almost 1700 distinct phosphopeptide species derived from 212 different members of the protein kinase superfamily. Analysis of VI 16832-retained proteins from the three cancer cell lines considerably increases the overall number of identified phosphorylation sites on protein kinases. Considering the sum of all phosphopeptide intensities as a measure for VI 16832-enriched protein amount, more than 80% is derived from protein kinases[2].
[1]. Kyla. A. L. Collins, et al. Proteomic Analysis Defines Kinase Taxonomies Specific for Subtypes of Breast Cancer. Apr. 1, 2017. [2]. Felix S. Oppermann, et al. Large-scale Proteomics Analysis of the Human Kinome. Mol Cell Proteomics. 2009 Jul; 8(7): 1751-1764.
Kinase experiment: | Cells are lysed in a volume of 35 to 40 mL per experiment. The protein amounts of the starting extracts used in the first and second experiments are: 435S, 85 and 120 mg; HCT116, 240 and 175 mg; MV4-11, 180 and 120 mg. Lysates are adjusted to 1 M NaCl prior to loading onto the VI 16832 column at a flow rate of 0.07 mL/min. Subsequent washing and elution steps are performed. Protein-containing elution fractions are lyophilized, resuspended in one tenth of the initial volume, and then desalted by protein precipitation prior to gel electrophoresis[2]. |
References: [1]. Kyla. A. L. Collins, et al. Proteomic Analysis Defines Kinase Taxonomies Specific for Subtypes of Breast Cancer. Apr. 1, 2017. | |
| Cas No. | 1430218-51-1 | SDF | |
| Canonical SMILES | O=C1C=CC2=CN=C(NC3=CC=C(OCCN)C=C3)N=C2N1C4C(C5)CCC5C4 | ||
| Formula | C22H25N5O2 | M.Wt | 391.47 |
| Solubility | DMSO : 83.3 mg/mL (212.79 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5545 mL | 12.7724 mL | 25.5447 mL |
| 5 mM | 0.5109 mL | 2.5545 mL | 5.1089 mL |
| 10 mM | 0.2554 mL | 1.2772 mL | 2.5545 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *